Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00769093 : Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
PhasePhase 1
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Signed Informed Consent Form

- Age equal or greater than 18 years

- Histologically confirmed high grade glioma

- Radiographic demonstration of disease progression following prior therapy of
temozolomide + radiation

- Patient scheduled for bevacizumab + standard IV chemotherapy therapy

- Bi-dimensionally measurable disease on gadolinium enhanced T1 weighted MR scans

- An interval of at least 4 weeks since prior surgical resection

- Patients corticosteroid dose must be 4 mg per day or less.

- Karnofsky performance status greater than or equal to 50

- Life expectancy greater than 12 weeks

- Ability to comply with study and follow-up procedures

Exclusion Criteria:

- Pregnant or nursing females

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Known liver function insufficiency, stage IV or V renal insufficiency

- Disease and Treatment History: Prior treatment with bevacizumab, or another vascular
endothelial growth factor (VEGF) or VEGFR-targeted agent; Need for urgent palliative
intervention for primary disease (e.g., impending herniation

- Bevacizumab Exclusion Criteria: History of hypertensive encephalopathy; New York
Heart Association (NYHA) Grade II or greater congestive heart failure (CHF); History
of myocardial infarction or unstable angina within 6 months prior to start of the
study; History of stroke or transient ischemic attack within 6 months prior to study
enrollment; Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
or recent peripheral arterial thrombosis within 6 months prior to start of the study;
Evidence of bleeding diathesis or coagulopathy; on therapeutic anti-coagulants.

- Subjects unable to undergo an MRI with contrast

- Ferumoxytol Exclusion Criteria: History of allergic reactions attributed to compounds
of similar chemical or biologic composition to ferumoxytol: parenteral iron,
parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide
preparations (Ferumoxytol Investigator's Drug Brochure, 2005). Patients with
significant drug or other allergies or autoimmune diseases may be enrolled at the
Investigator's discretion

- Subjects with known or suspected iron overload (genetic hemochromatosis or history of
multiple transfusions).Patients with transferrin saturation greater than 60%

- Inability or unwillingness to undergo the complete series of imaging sessions.
Inability or unwillingness to return to the neuro-oncology clinic at Oregon Health
and Science University (OHSU) for the one month follow-up
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00769093      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740